李燚绯

[摘要] 目的 分析厄贝沙坦治疗糖尿病蛋白尿的临床效果。 方法 选取2018年3月—2019年4月该院收治的糖尿病蛋白尿患者76例为研究对象，随机单双数法分为对照组38例，进行常规治疗，观察组38例，予以厄贝沙坦治疗，对比患者治疗效果、不良反应率。 结果 治疗前两组患者尿微量白蛋白等指标均差异无统计学意义（P>0.05）;治疗后观察组患者尿微量白蛋白显著低于对照组，差异有统计学意义（P<0.05）;治疗后两组患者BUN（血尿素氮）、Scr（血肌酐）、K+（血清钾）差异无统计学意义（P>0.05）;两组患者不良反应率无，差异无统计学意义（P>0.05）;观察组患者总有效率显著高于对照组，差异有统计学意义（P<0.05）。结论 糖尿病蛋白尿患者予以厄贝沙坦干预后总有效率有显著提升，且蛋白尿得到控制，不良反应较少，有应用价值。

[关键词] 厄贝沙坦;糖尿病蛋白尿;肾脏微血管病变;不良反应率

[中图分类号] R587.1          [文献标识码] A          [文章編号] 1672-4062（2020）05（b）-0069-03

Clinical Effect of Irbesartan in the Treatment of Diabetic Proteinuria

LI Yi-fei

Department of Geriatrics， Affiliated Hospital of Changchun University of Traditional Chinese Medicine， Changchun， Jilin Province， 130021 China

[Abstract] Objective To analyze the clinical effect of irbesartan in the treatment of diabetic proteinuria. Methods A total of 76 diabetic proteinuria patients admitted in the hospital from March 2018 to April 2019 were selected as the research subjects. The random odd and even number method was used to divide the control group into 38 cases for routine treatment and the observation group for 38 cases. The treatment was compared with the treatment effect and adverse reaction rate. Results There was no significant difference in urine microalbumin and other indicators between the two groups of patients before treatment， and there was no statistical significance （P>0.05）. The urine microalbumin in the observation group was significantly lower than that in the control group after treatment， and the difference was statistically significant（P<0.05） ; After treatment， BUN （blood urea nitrogen）， Scr （blood creatinine）， K+ （serum potassium） were not significantly different between the two groups， there was no statistical significance （P>0.05）; there was no statistically significant difference in adverse reaction rates between the two groups. The difference was not statistically significant （P>0.05）; the total effective rate of patients in the observation group was significantly higher than that in the control group， and the difference was statistically significant（P<0.05）. Conclusion The total effective rate of diabetic proteinuria patients is significantly improved after intervention with irbesartan， and proteinuria is controlled， with fewer adverse reactions， and has application value.

[Key words] Irbesartan; Diabetic proteinuria; Renal microangiopathy; Adverse reaction rate

糖尿病为全球范围内严重疾病，患者常会合并肾脏微血管病变，肾脏功能衰竭为糖尿病肾病主要病因。糖尿病肾病患者则会出现机体代谢产生紊乱，晚期可发展为末终期肾病。糖尿病蛋白尿则为糖尿病肾病的重要指标，当患者尿液内微量蛋白超出肾小管吸收能力时，即表现為蛋白尿。现阶段对此种疾病治疗采用常规药物控制蛋白尿，降低肾脏损伤为主，但当患者出现感冒等问题时则会加剧，治疗效果有限。有学者提出，厄贝沙坦可有效控制患者蛋白尿，无严重不良反应，整体干预效果良好[1]。现选取2018年3月—2019年4月该院均有糖尿病史的糖尿病蛋白尿患者76例作为研究对象，随机分为对照组和观察组，各组38例，分析不同干预方式效果，报道如下。

1  资料与方法

1.1  一般资料

选取该院糖尿病蛋白尿患者76例，患者均有糖尿病史，同时患者尿标本白蛋白/肌酐为30～299 μg/mg;血肌酐≤100 μmol/L[2]。纳入标准……